Perron Pharmaceuticals Private Limited
About Perron Pharmaceuticals Private Limited
Data last updated:
Perron Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 April 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24233DL2008PTC176181. Its GSTIN is 07AAECP6504D1ZQ (Delhi).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Tarun Kumar Garg and Anita.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C – 33H Street No. – 5 Jagatpuri Extention Shahdara, Delhi, India – 110093.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.59 Lakh, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹86,760 (net margin 1.4%) and EBITDA of ₹1.25 Lakh (EBITDA margin 2%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 10% over five years.
Court records list 1 case involving the company, including 1 filed against it.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Perron Pharmaceuticals Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressC – 33H Street No. – 5 Jagatpuri Extention Shahdara, Delhi, India – 110093
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Perron Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Perron Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Perron Pharmaceuticals Private Limited, buy the company report.
Financials of Perron Pharmaceuticals Private Limited
FY 2025 filings availablePerron Pharmaceuticals Private Limited reported revenue of ₹62.59 Lakh (up 13% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 13% growth in the latest year. EBITDA rose 34% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.25 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹86,760 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2% | ||||
| Net Profit Margin | 1.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Perron Pharmaceuticals Private Limited, buy the company report.
Board of directors of Perron Pharmaceuticals Private Limited
Perron Pharmaceuticals has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Tarun Kumar Garg | Director | 01 Apr 2008 | 18 Years 6 Months | Current |
| Anita Also directs: Ddu Security Private Limited | Director | 27 Oct 2016 | 9 Years 11 Months | Current |
Peer comparison
Perron Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fizex Pharmaceuticals Private Limited | ₹62.62 Lakh (FY 2018) | 232.0% | Patna, Bihar, India | |||
| Perron Pharmaceuticals Private Limitedthis company | ₹62.59 Lakh (FY 2025) | ₹86,760 | 1.4% | 13.0% | Delhi, India | |
| Reetosh Pharmaceuticals Private Limited | ₹62.54 Lakh (FY 2025) | 16.0% | Ranchi, Jharkhand, India | |||
| Hygeia Labs Private Limited | ₹62.46 Lakh (FY 2025) | -9.0% | Delhi, India | |||
| Allegro Pharmaceuticals Private Limited | ₹62.32 Lakh (FY 2023) | 3.0% | Kozhikode, Kerala, India |
To see the full peer comparison of Perron Pharmaceuticals Private Limited, buy the company report.
Auditor
Perron Pharmaceuticals Private Limited is audited by P P SINGH & ASSOCIATES for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| P P SINGH & ASSOCIATES | FY 2019 | 019336N |
Shareholding
The shareholding of Perron Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2019, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Perron Pharmaceuticals Private Limited, buy the company report.
Legal cases
Perron Pharmaceuticals Private Limited has 1 court case on record: 1 filed against it. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed against the company by M/S Perron Pharmaceutical | Disposed |
To see the full case history of Perron Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Perron Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Perron Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECP6504D1ZQ | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Perron Pharmaceuticals Private Limited, buy the company report.
Recent activity
Perron Pharmaceuticals Private Limited has 14 board changes on record since 2008: 8 appointments and 6 cessations. The latest: Anita was appointed as Director on 27 Oct 2016.
5 earlier events are in the company report.
Frequently asked questions
Perron Pharmaceuticals is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 April 2008 (18+ years old) and is registered under CIN U24233DL2008PTC176181.
Perron Pharmaceuticals has 2 current directors:
- Tarun Kumar Garg - Director
- Anita - Director
The latest financial statements of Perron Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Perron Pharmaceuticals is 07AAECP6504D1ZQ, registered in Delhi.
The CIN (Corporate Identification Number) of Perron Pharmaceuticals is U24233DL2008PTC176181. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Perron Pharmaceuticals has 1 court case on record: 1 filed against it.
Perron Pharmaceuticals was incorporated on 01 April 2008, making it 18+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Perron Pharmaceuticals by revenue are Fizex Pharmaceuticals Private Limited, Reetosh Pharmaceuticals Private Limited, Hygeia Labs Private Limited, Allegro Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).
Anita was appointed as Director on 27 Oct 2016. Varun Kumar Garg ceased to be Additional Director on 27 Oct 2016. Praveen Sharma ceased to be Director on 27 Jan 2014. Perron Pharmaceuticals has 14 board changes on record in total.
The registered office of Perron Pharmaceuticals is at C – 33H Street No. – 5 Jagatpuri Extention Shahdara, Delhi, India – 110093.
Perron Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.